
-
Japan had hottest June on record: weather agency
-
Asian stocks rise on trade deal hopes, Tokyo hit by Trump warning
-
Thailand's PM suspended by Constitutional Court
-
Blur will return to musical oasis, says drummer Rowntree
-
CBEX crypto scam: AI-hyped Ponzi scheme defrauds African investors
-
Inzaghi hails 'extraordinary' Al Hilal after City upset
-
Man City, Inter Milan crash out of Club World Cup in last 16
-
North Korea's Kim shown honouring troops killed in Russia-Ukraine war
-
Saudi's Al Hilal knock Man City out of Club World Cup in huge shock
-
'In our blood': Egyptian women reclaim belly dance from stigma
-
Online memorial for children dead in Hiroshima, Nagasaki
-
US Senate in final push to pass Trump spending bill
-
Asian stocks rise on trade deal hopes, Tokyo hit by tariff warning
-
Hong Kong rights record under fire as it marks China handover anniversary
-
Bangladeshis cling to protest dreams a year after revolution
-
Djokovic, Sinner enter Wimbledon fray
-
European security tops Denmark's EU presidency priorities
-
France expecting peak temperatures as heatwave hits Europe
-
Germany eye return to women's football summit at Euro 2025
-
'Every day I see land disappear': Suriname's battle to keep sea at bay
-
England feel pressure to perform at Euros as stars pull out
-
Clashes in Istanbul over alleged 'Prophet Mohammed' cartoon
-
India face 'last-minute' Bumrah call as they bid to level England series
-
Dortmund up against 'superstar' Ramos, aggressive Monterrey: Kovac
-
US judge orders Argentina to sell 51% stake in oil firm YPF
-
DEA BUSTED!! While Chinese Marijuana Cartels Spread Right Under DEA's Nose, FDA CANNABIS RESEARCH BLOCKED
-
Proenkephalin A 119-159 (penKid) Leads the Way in Predicting Graft Outcomes for Kidney Transplant Recipients
-
DASA, Latin America's Largest Diagnostic Provider, Selects AGFA HealthCare's Enterprise Imaging Platform in Flagship Agreement
-
Record Financing for NeXtWind: €1.4 Billion for the Expansion of Wind Energy in Germany
-
Pantheon Resources PLC Announces Change of Registered Office
-
EPA employees accuse Trump administration of 'ignoring' science
-
US Senate in final slog towards vote on Trump spending bill
-
Over 14 million people could die from US foreign aid cuts: study
-
End of the line for Britain's royal train
-
FIFPro warns of 'wake-up call' over extreme heat at Club World Cup
-
Sean Combs sex trafficking jury ends first day without decision
-
Fluminense stun Inter Milan to reach Club World Cup quarters
-
Thailand's ruling political dynasty faces day of legal peril
-
NASA eyes summer streaming liftoff on Netflix
-
Trump dismantles Syria sanctions program as Israel ties eyed
-
Meta's AI talent war raises questions about strategy
-
Twenty bodies, some headless, found in Mexican cartel bastion
-
Gaza rescuers say Israeli forces kill over 50 as ceasefire calls mount
-
Alcaraz survives scare, Sabalenka cruises on Wimbledon's hottest opening day
-
Only Messi can shirk defending: warns Monterrey coach before Dortmund clash
-
White House says Canada 'caved' to Trump on tech tax
-
Eight-country coalition aims to tax luxury air travel
-
Wimbledon qualifier Tarvet vows to get creative with expenses
-
Iran unleashes 'wave of repression' after Israel war: activists
-
Alcaraz survives Fognini scare to launch Wimbledon title defence

Possible antidote discovered for deadliest mushroom: study
Researchers said on Tuesday that an already widely used medical dye reduces the poisonous effects of death cap mushrooms in mice, raising hopes of the first targeted antidote for the world's deadliest mushroom.
The China-led team said the dye, which has yet to be tested as an antidote on humans but has already been approved by the US Food and Drug Administration (US FDA) for other uses, has the potential to "save many lives".
Amanita phalloides, commonly known as death caps, are estimated to cause more than 90 percent of all deaths from mushroom poisoning worldwide.
They often resemble other species of mushrooms that people like to pick in the wild -- but eating just half of one can cause deadly failure of the liver or kidneys.
While originally native to Europe, death caps have spread across the world, causing more than 38,000 illnesses and nearly 800 deaths in China alone between 2010 and 2020.
For a new study published in the journal Nature Communications, the researchers sought to target alpha-amanitin, the main toxin produced by the mushrooms.
They used genome-wide CRISPR screening, a relatively new technique that has helped researchers understand the role specific genes play in infections and poisonings.
The team had previously used the technology to find a potential antidote for the box jellyfish, one of the world's most venomous animals.
The CRISPR screening identified that the protein STT3B was a key culprit in the toxic effects of death cap poisoning.
The team searched through a database of drugs already approved by the US FDA and found one that could potentially block the protein.
- 'Unexpected connection' -
It is a fluorescent dye called indocyanine green, which is administered intravenously. It has been widely used for decades in the US, Europe and elsewhere for diagnostic imaging, allowing doctors to measure liver and heart function.
Qiaoping Wang, a researcher at China's Sun Yat-sen University and senior author of the study, told AFP that "upon discovering this unexpected connection, the research team was understandably taken aback".
The team tested the antidote first on liver cells in a petri dish, then on mice.
In both cases, it "demonstrated significant potential in mitigating the toxic impact" of mushroom poisoning, Wang said.
"This molecule holds immense potential for treating cases of human mushroom poisoning and could mark the first-ever specific antidote with a targeted protein," he said.
"It could save many lives if it is as effective in humans as in mice."
The team now intends to conduct trials on humans using the dye as a death cap antidote.
An extract from milk thistle seeds called silibinin has previously been used to treat death cap poisoning, but exactly how it works has remained unclear.
L.Harper--AMWN